CH3 BioSystems is a biotechnology company based on an entirely new patent-protected chemical technology designed to identify and commercialize drug and diagnostic candidates.
BLOG SERIES | PART 5 OF 5 Part 5: What This Means for Your Research The scientific and practical takeaways from a study powered by CH3 Biosystems Blog post by Pranitha Bhuthkuri Click Here to Learn More! Next week: Part 5: What This Means for Your Research The scientific and practical takeaways from a study […]
BLOG SERIES | PART 4 OF 5 Part 4: Four Findings That Changed the Picture The major discoveries made possible by a precision E0771-based brain metastasis model Blog post by Pranitha Bhuthkuri Click Here to Learn More! Next week: Part 5: What This Means for Your Research The scientific and practical takeaways from a study […]
CH3 BIOSYSTEMS LLC Featured in Peer-Reviewed Research How the E0771 Cell Line from CH3 Biosystems Powered a Landmark Brain Cancer Study Published in Cell Reports, March 2025 | Golomb et al. Blog post by Pranitha Bhuthkuri The Big Picture A landmark 2025 study published in Cell Reports used the E0771 breast cancer cell line, […]
CH3 BIOSYSTEMS — RESEARCH SPOTLIGHT | APRIL 2026 How E0771 Breast Cancer Cells Revealed a Hidden Immune Escape Route in the Lung By Pranitha Bhuthkuri A landmark 2026 study from the Weizmann Institute of Science uses our E0771 cells (SKU: 94A001) murine breast adenocarcinoma cells to uncover a surprising mechanism by which metastatic […]
Immunoaffinity Purification of Methylarginine Proteins/Peptides by Protein A Sepharose By: Daniyal Kashif Protein affinity purification Protein A Sepharose is an affinity resin that is widely employed for the selective enrichment of immunoglobulin G (IgG) and its various subclasses from horse, rabbit, or human antiserum. More specifically, this purification technique involves the covalent immobilization of Protein […]
If you need to authenticate your cell line for an NIH grant, or if you are looking to satisfy your IACUC prior to clearance of your transplantation studies, contact CH3 BioSystems. You can even design your own test panel! We have a broad array of options for you (see below). In addition, species-specific PCR evaluation […]
This week’s blog post highlights a recent study by Lim et al. This proteome-wide analysis of protein arginine methylation in colorectal cancer based on human surgical specimens is another example of the developments occurring in our field with real impact on disease diagnosis. For histological detection of the methylation status of colon cancer, we recommend […]
CH3 BioSystems is excited about an important review article recently published by Majumder et al. that helps to explain the role of methylarginine modification in the functional regulation the fragile X family of proteins with implications for neurodevelopment and cancer. In conjunction with phospho-serine modifications of these methyl-proteins, the molecular mechanisms involved are likely to […]
A ground-breaking report from scientists at Glaxo and Epizyme has now revealed that the PRMT1 inhibitor, GSK3368715, exhibits potent anti-tumor activity. Extensive chemical and cellular studies support the usefulness of the new chemical compound as a First-In-Class therapeutic agent. Also described in the report are experiments that implicate the endogenous metabolic inhibitor, methyl-thioadenosine (MTA), in […]
After removing E0771 cells from cell culture using sterile technique, the cells are counted and injected into a healthy mouse via the mammary pads (typically the fourth mammary pad) or intravenously in the tail vein [1-8]. To see the full effects of tumor growth, 1 x 105 to 1 x 106 must be used for […]
